母体免疫接种佐剂RSV预融合F蛋白可保护子代并改变先天性与T细胞免疫
为评估母体RSV预融合F蛋白疫苗对子代的保护及免疫影响,研究者对免疫母鼠的子代进行RSV攻击并追踪免疫应答。结果显示母体免疫对子代安全有效,但高水平且衰减的母体抗体与不同的先天性和T细胞免疫相关。
要点
- 母体RSV PreF免疫可为子代提供针对RSV攻击的保护。
- 母体抗体水平高低及衰减影响子代先天性与T细胞免疫。
- 婴儿2-6月龄RSV感染高发且直接接种效果有限,母体免疫具优势。
核心结论
- 母体免疫RSV PreF疫苗对RSV攻击的子代安全有效。
- 高水平且衰减的母体抗体与子代先天性和T细胞免疫差异相关。
研究设计与样本
- 研究为动物实验:对免疫母鼠所生子代进行RSV攻击并随时间分析免疫应答。
主要发现
- 母体免疫子代在RSV攻击后表现出安全性及有效性。
- 高且衰减的母体抗体水平与不同的先天性和T细胞免疫相关。
临床怎么用
- 支持母体RSV PreF免疫作为婴儿出生后早期保护策略。
- 需关注母体抗体水平对子代免疫应答的潜在影响。
局限性
- 研究为动物模型,结果外推至人类需谨慎。
- 母体抗体影响子代免疫的具体机制未完全阐明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Respiratory syncytial virus (RSV) commonly causes severe respiratory tract infections in infants, peaking between 2 and 6 months of age; an age at which direct vaccination is unlikely to be effective. Maternal immunization can deliver high levels of antibodies to newborns, providing immediate protection. Following natural infection, antibodies targeting the prefusion conformation of RSV F protein (PreF) have the greatest neutralizing capacity and thus, may provide infants with a high degree of RSV protection when acquired through maternal vaccination. However, the influence of anti-PreF maternal antibodies on infant immunity following RSV exposure has not been elucidated. To address this knowledge gap, offspring born to dams immunized with a RSV PreF vaccine formulation were challenged with RSV and their immune responses were analyzed over time. These studies demonstrated safety and efficacy for RSV-challenged, maternally-immunized offspring but high and waning maternal antibody levels were associated with differential innate and T cell immunity.
引用
- Eichinger KM, Kosanovich JL, Lipp MA, et al. Maternal immunization with adjuvanted RSV prefusion F protein effectively protects offspring from RSV challenge and alters innate and T cell immunity. Vaccine. 2020. PMID: 33129608. doi:10.1016/j.vaccine.2020.10.065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。